150 related articles for article (PubMed ID: 36200265)
1. A novel subtype to predict prognosis and treatment response with DNA driver methylation-transcription in ovarian cancer.
Xu Z; Zhang L; Wang M; Huang Y; Zhang M; Li S; Wang L; Li K; Hou Y
Epigenomics; 2022 Sep; 14(18):1073-1088. PubMed ID: 36200265
[TBL] [Abstract][Full Text] [Related]
2. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract][Full Text] [Related]
3. A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
Wang X; Xu Z; Zhao S; Song J; Yu Y; Yang H; Hou Y
J Cancer Res Clin Oncol; 2024 May; 150(5):269. PubMed ID: 38777866
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Candidate DNA Methylation Cancer Driver Genes.
Pan H; Renaud L; Chaligne R; Bloehdorn J; Tausch E; Mertens D; Fink AM; Fischer K; Zhang C; Betel D; Gnirke A; Imielinski M; Moreaux J; Hallek M; Meissner A; Stilgenbauer S; Wu CJ; Elemento O; Landau DA
Cancer Discov; 2021 Sep; 11(9):2266-2281. PubMed ID: 33972312
[TBL] [Abstract][Full Text] [Related]
5. Assessing the clinical utility of multi-omics data for predicting serous ovarian cancer prognosis.
Zhang Z; Wei Z; Zhao L; Gu C; Meng Y
J Obstet Gynaecol; 2023 Dec; 43(1):2171778. PubMed ID: 36803381
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
Yang X; Zheng M; Ning Y; Sun J; Yu Y; Zhang S
J Transl Med; 2023 Jul; 21(1):456. PubMed ID: 37434173
[TBL] [Abstract][Full Text] [Related]
7. MMDAE-HGSOC: A novel method for high-grade serous ovarian cancer molecular subtypes classification based on multi-modal deep autoencoder.
Wang HQ; Li HL; Han JL; Feng ZP; Deng HX; Han X
Comput Biol Chem; 2023 Aug; 105():107906. PubMed ID: 37336028
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis.
Wang YA; Neff R; Song WM; Zhou X; Vatansever S; Walsh MJ; Chen SH; Zhang B
FEBS Open Bio; 2023 Apr; 13(4):617-637. PubMed ID: 36637997
[TBL] [Abstract][Full Text] [Related]
9. A methylation-driven genes prognostic signature and the immune microenvironment in epithelial ovarian cancer.
Tan M; Wang S; Li F; Xu H; Gao J; Zhu L
Carcinogenesis; 2022 Aug; 43(7):635-646. PubMed ID: 35639961
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
[TBL] [Abstract][Full Text] [Related]
11. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
[TBL] [Abstract][Full Text] [Related]
12. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
13. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
[TBL] [Abstract][Full Text] [Related]
16. Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data.
Zhang Z; Huang K; Gu C; Zhao L; Wang N; Wang X; Zhao D; Zhang C; Lu Y; Meng Y
Sci Rep; 2016 May; 6():26001. PubMed ID: 27184229
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives.
Papakonstantinou E; Androutsopoulos G; Logotheti S; Adonakis G; Maroulis I; Tzelepi V
Curr Mol Pharmacol; 2021; 14(6):1013-1027. PubMed ID: 32778046
[TBL] [Abstract][Full Text] [Related]
18. ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment.
Ye X; An L; Wang X; Zhang C; Huang W; Sun C; Li R; Ma H; Wang H; Gao M
Front Oncol; 2021; 11():675104. PubMed ID: 34094977
[TBL] [Abstract][Full Text] [Related]
19. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
20. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
